Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4088-4095

  Wierda, William G ^a   O'Brien, Susan ^a   Wang, Xuemei ^a   Faderl, Stefan ^a   Ferrajoli, Alessandra ^a   Do, Kim Anh ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Thomas, Deborah ^a   Koller, Charles A ^a   Burger, Jan A ^a   Lerner, Susan ^a   Schlette, Ellen ^a   Abruzzo, Lynne ^a   Kantarjian, Hagop M ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CREATININE; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; AXILLARY LYMPH NODE; B LYMPHOCYTE; CANCER CENTER; CANCER PATIENT; CERVICAL LYMPH NODE; CHROMOSOME 11Q; CHROMOSOME 17P; CHRONIC LYMPHATIC LEUKEMIA; CREATININE BLOOD LEVEL; DELETION MUTANT; EARLY INTERVENTION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE MUTATION; HUMAN; INGUINAL LYMPH NODE; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLOW CYTOMETRY; GENE DELETION; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NOMOGRAMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TEXAS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 80755127112     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.9002     Document Type: Article

References (25)

1. Wierda WG, O'Brien S, Wang X, et al.: Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109:4679-4685, 2007 (Pubitemid 46827758)
2. Wierda WG, O'Brien S, Wang X, et al.: Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 27:1637-1643, 2009
3. Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000 (Pubitemid 32064784)
4. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999 (Pubitemid 29430400)
5. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999 (Pubitemid 29430399)
6. Durig J, Nuckel H, Cremer M, et al.: ZAP- 70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 17:2426-2434, 2003 (Pubitemid 38072581)
7. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003 (Pubitemid 36514707)
8. Del Poeta G, Maurillo L, Venditti A, et al.: Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98:2633-2639, 2001
9. Cheson BD, Bennett JM, Grever M, et al.: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
10. Hallek M, Cheson BD, Catovsky D, et al.: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
11. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004 (Pubitemid 39096916)
12. Lin KI, Tam CS, Keating MJ, et al.: Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113:3168-3171, 2009
13. Admirand JH, Rassidakis GZ, Abruzzo LV, et al.: Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 17:954-961, 2004 (Pubitemid 38993780)
14. Grambsch P, Louis TA, Bostick RM, et al.: Statistical analysis of proliferative index data in clinical trials. Stat Med 13:1619-1634, 1994 (Pubitemid 24275841)
15. Kattan MW, Eastham JA, Stapleton AM, et al.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998 (Pubitemid 28259189)
16. Molica S, Mauro FR, Callea V, et al.: A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. Leuk Lymphoma 46:553-560, 2005 (Pubitemid 40584871)
17. Del Giudice I, Morilla A, Osuji N, et al.: Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 104:2124-2132, 2005 (Pubitemid 41579958)
18. Krober A, Bloehdorn J, Hafner S, et al.: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24:969-975, 2006 (Pubitemid 46646223)
19. Morilla A, Gonzalez de Castro D, Del Giudice I, et al.: Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. Leuk Lymphoma 49:2108-2115, 2008
20. Rassenti LZ, Jain S, Keating MJ, et al.: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia Blood 112:1923-1930, 2008
21. Morabito F, Cutrona G, Gentile M, et al.: Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. Br J Haematol 146:44-53, 2009
22. Letestu R, Lévy V, Eclache V, et al.: Prognosis of Binet stage A chronic lymphocytic leukemia patients: The strength of routine parameters. Blood 116:4588-4590, 2010
23. Molica S, Mauro FR, Callea V, et al.: The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: The GIMEMA experience. Haematologica 95:464-469, 2010
24. Shanafelt TD, Jenkins G, Call TG, et al.: Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 115:363-372, 2009
25. Bulian P, Tarnani M, Rossi D, et al.: Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. Hematol Oncol 29:91-99, 2011